Related Experiment Video
Updated: Nov 12, 2025
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
11.2K
Long QT syndrome type 2: mechanism-based therapies
Kofi Oliver Cox1, Brian Xiangzhi Wang2
1Department of Medicine, St George's, University of London, London, UK.
Future Cardiology
|March 19, 2021
Summary
Long QT syndrome type 2 is a dangerous heart rhythm disorder that can cause sudden cardiac death. Current treatments manage symptoms, but new therapies targeting hERG channel dysfunction are being explored.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Long QT syndrome type 2 (LQTS2) is a life-threatening cardiac electrophysiology disorder.
- It can lead to sudden cardiac death due to QT prolongation and dangerous arrhythmias.
- LQTS2 often remains undiagnosed until a critical clinical event occurs.
Purpose of the Study:
- To review the pathophysiology, diagnosis, and current management of LQTS2.
- To analyze promising, mechanism-based therapeutic strategies for LQTS2.
- To highlight the need for treatments targeting hERG channel dysfunction.
Main Methods:
- Literature review of LQTS2 pathophysiology and diagnosis.
- Analysis of current treatment modalities, including beta-adrenergic blockade.
- Evaluation of emerging therapeutic approaches targeting hERG channels.
Main Results:
- LQTS2 is caused by dysfunction in hERG channels, crucial for cardiac repolarization.
- Current treatments focus on symptom management, lacking a mechanism-based approach.
- Several potential therapies targeting hERG channel dysfunction show promise.
Conclusions:
- LQTS2 poses a significant risk of sudden cardiac death due to arrhythmias.
- There is a critical unmet need for mechanism-based therapies for LQTS2.
- Targeting hERG channel dysfunction represents a promising avenue for future LQTS2 treatments.
Related Concept Videos
01:28Mechanism of Cardiac Arrhythmias
1.4K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.4K
01:25Dysrhythmias VI: Management of Dysrhythmias
206
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
206
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.5K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.5K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
248
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
248
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.2K